Details of the Drug Reposition

General Information of This Drug (ID: DMJUNY5)

Drug Name
Cefpodoxime   DMJUNY5
Synonyms
CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
7 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal pneumonia DIS2EKMJ N.A. Approved [1]
Staphylococcus aureus infection DISK6PTH N.A. Approved [1]
Pars planitis DISF45DN N.A. Approved [1]
Acute maxillary sinusitis DISEUB5R N.A. Approved [1]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
Acute otitis media DISL8D8G AB00 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gonorrhea DISQ5AO6 1A7Z Discontinued in Phase 2 [3]
Pharyngitis DISSN548 CA02.Z Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial pneumonia DISPW7PH CA40.0 Discontinued in Phase 1 [5]
------------------------------------------------------------------------------------

References

1 Cefpodoxime FDA Label
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 ClinicalTrials.gov (NCT00520845) Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
4 ClinicalTrials.gov (NCT00038142) Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
5 Pentoxifylline for Acute Alcoholic Hepatitis (AAH)